{"totalCount":6,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06924970","orgStudyIdInfo":{"id":"AG946-C-003"},"secondaryIdInfos":[{"id":"2024-519746-70-01","type":"CTIS"}],"organization":{"fullName":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)","officialTitle":"A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-05","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-04-10","studyFirstSubmitQcDate":"2025-04-10","studyFirstPostDateStruct":{"date":"2025-04-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-27","lastUpdatePostDateStruct":{"date":"2026-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD."},"conditionsModule":{"conditions":["Sickle Cell Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":56,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Tebapivat 2.5 milligrams (mg)","type":"EXPERIMENTAL","description":"Participants will receive 2.5 mg tebapivat orally, once daily (QD) for 12-weeks in the double-blind (DB) period. Participants who complete the DB Period will be eligible to receive the same dose in the Open-Label Extension (OLE) period for up to 52 weeks.","interventionNames":["Drug: Tebapivat"]},{"label":"Tebapivat 5.0 mg","type":"EXPERIMENTAL","description":"Participants will receive 5.0 mg tebapivat orally, QD, for 12-weeks in the DB period. Participants who complete the DB Period will be eligible to receive the same dose in the OLE period for up to 52 weeks.","interventionNames":["Drug: Tebapivat"]},{"label":"Tebapivat 7.5 mg","type":"EXPERIMENTAL","description":"Participants will receive 7.5 mg tebapivat orally, QD, for 12-weeks in the DB period. Participants who complete the DB Period will be eligible to receive the same dose in the OLE period for up to 52 weeks.","interventionNames":["Drug: Tebapivat"]},{"label":"Tebapivat Matched Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive a matched placebo, orally, QD, for 12-weeks in the DB period. Participants who complete the DB Period will be randomized in 1:1:1 to receive tebapivat 2.5 mg QD, tebapivat 5.0 mg QD, or tebapivat 7.5 mg QD in the OLE period for up to 52 weeks","interventionNames":["Drug: Tebapivat","Drug: Tebapivat Matched Placebo"]}],"interventions":[{"type":"DRUG","name":"Tebapivat","description":"Oral tablets.","armGroupLabels":["Tebapivat 2.5 milligrams (mg)","Tebapivat 5.0 mg","Tebapivat 7.5 mg","Tebapivat Matched Placebo"],"otherNames":["AG-946"]},{"type":"DRUG","name":"Tebapivat Matched Placebo","description":"Oral tablets.","armGroupLabels":["Tebapivat Matched Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Hb Response","timeFrame":"Baseline, Week 10 through Week 12"}],"secondaryOutcomes":[{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to Week 72"},{"measure":"Average Change From Baseline in Hb Concentration","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Indirect Bilirubin","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Lactate Dehydrogenase (LDH)","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Absolute Reticulocyte Count","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Percent Reticulocytes","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Erythropoietin","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Patient Reported Outcomes Measurement Information System® (PROMIS) Fatigue 13a Short Form Score","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in PROMIS Pain Intensity 1a Score","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Average Change From Baseline in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) Pain Impact Score","timeFrame":"Baseline, Week 10 through Week 12"},{"measure":"Plasma Concentration of Tebapivat","timeFrame":"Pre-dose and at multiple timepoints post-dose up to Week 8"},{"measure":"Maximum (Peak) Concentration (Cmax) of Tebapivat","timeFrame":"Pre-dose and at multiple timepoints post-dose up to Week 8"},{"measure":"Time to Cmax (tmax) of Tebapivat","timeFrame":"Pre-dose and at multiple timepoints post-dose up to Week 8"},{"measure":"Area Under the Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t) of Tebapivat","timeFrame":"Pre-dose and at multiple timepoints post-dose up to Week 8"},{"measure":"Whole Blood Concentrations of 2,3-Diphosphoglycerate (2,3-DPG)","timeFrame":"Pre-dose and at multiple timepoints post-dose up to Week 8"},{"measure":"Whole Blood Concentrations of Adenosine Triphosphate (ATP)","timeFrame":"Pre-dose and at multiple timepoints post-dose up to Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Documented diagnosis of SCD (HbSS, HbSC \\[combined heterozygosity for hemoglobins S and C\\], sickle hemoglobin \\[HbS\\]/β0-thalassemia, HbS/β+-thalassemia, or other sickle cell syndrome variants).\n* Hemoglobin ≥5.5 and ≤10.5 grams per decilitre (g/dL). Hemoglobin concentration must be based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the screening period.\n* If taking hydroxyurea, the hydroxyurea dose must be stable for at least 90 days before randomization. Discontinuation of hydroxyurea requires a 90-day washout before providing informed consent.\n\nKey Exclusion Criteria:\n\n* Receiving regularly scheduled red blood cell (RBC) transfusion therapy (also termed chronic, prophylactic, or preventative transfusion); episodic transfusion in response to worsened anemia or vaso-occlusive crisis (VOC) is permitted. Additionally, a participant who requires episodic transfusion(s) may not have received a transfusion(s) within 60 days before providing informed consent or during the screening period.\n* \\>10 sickle cell pain crisis (SCPCs) in the 12 months before providing informed consent.\n* Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥10 weeks before randomization.\n* Hospitalized for an SCPC and/or other vaso-occlusive event within 14 days before providing informed consent or within 14 days before randomization. If an SCPC occurs during the screening period, the screening period may be extended with Medical Monitor approval.\n* Receiving treatment with voxelotor, crizanlizumab, or L-glutamine within 90 days before randomization.\n* Platelet count \\<lower limit of normal (LLN) for the local laboratory or \\<150×109/liter (L) (whichever is lower) during screening. Platelet transfusions received within 28 days before consent or during screening.\n* Receiving treatment with hematopoietic stimulating agents within 90 days before randomization.\n* Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any conditioning regimen.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Agios Medical Affairs","role":"CONTACT","phone":"833-228-8474","email":"medinfo@agios.com"}],"locations":[{"facility":"UCHealth at University of Colorado Anschutz Medical Campus","status":"RECRUITING","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"UConn Health","status":"RECRUITING","city":"Farmington","state":"Connecticut","zip":"06030-0001","country":"United States","geoPoint":{"lat":41.71982,"lon":-72.83204}},{"facility":"Children's National Hospital","status":"RECRUITING","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"MedStar Washington Hospital Center","status":"RECRUITING","city":"Washington D.C.","state":"District of Columbia","zip":"20010","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Ann & Robert H. Lurie Children's Hospital of Chicago","status":"RECRUITING","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Boston Medical Center & Boston University School of Medicine","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Henry Ford Health System","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Children's Hospital of Michigan","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48304","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Icahn School of Medicine at Mt. Sinai","status":"RECRUITING","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Montefiore Medical Center","status":"RECRUITING","city":"The Bronx","state":"New York","zip":"10460","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Thomas Jefferson University Hospital","status":"RECRUITING","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Pittsburgh Medical Center","status":"RECRUITING","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Lifespan at Rhode Island Hospital","status":"RECRUITING","city":"Providence","state":"Rhode Island","zip":"02903-4923","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Prisma Health Cancer Institute - Farris Road","status":"RECRUITING","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"University of Texas Health Science Center of Houston","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Fred Hutchinson Cancer Center, University of Washington","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"CHR de la Citadelle","status":"RECRUITING","city":"Liège","state":"Wallonne","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Clinique CHC MontLégia","status":"RECRUITING","city":"Liège","state":"Wallonne","zip":"4420","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Scarborough Health Network - Centenary Hospital","status":"RECRUITING","city":"Scarborough Village","state":"Ontario","zip":"M1E 4B9","country":"Canada","geoPoint":{"lat":43.73899,"lon":-79.22124}},{"facility":"CHU Montreal","status":"RECRUITING","city":"Montreal","state":"Quebec","zip":"H2X 3E4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"McGill University Health Center","status":"RECRUITING","city":"Montreal","state":"Quebec","zip":"H4A 3J1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Hôpital Edouard Herriot, CHU de Lyon","status":"RECRUITING","city":"Lyon","state":"Auvergne-Rhône-Alpes","zip":"69003","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Institut Universitaire du Cancer de Toulouse - Oncopole","status":"RECRUITING","city":"Toulouse","state":"Midi Pyrenees","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"CHU Hôpital Henri Mondor","status":"RECRUITING","city":"Créteil","state":"Île-de-France Region","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"St. James Hospital","status":"RECRUITING","city":"Dublin","state":"Leinster","zip":"D08 A978","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Amsterdam Universitair Medisch Centrum, Locatie AMC","status":"RECRUITING","city":"Amsterdam","state":"North Holland","zip":"1105AZ","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Erasmus MC","status":"RECRUITING","city":"Rotterdam","state":"South Holland","zip":"3015 GD","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Universitair Medisch Centrum Utrecht","status":"RECRUITING","city":"Utrecht","zip":"3584 CX","country":"Netherlands","geoPoint":{"lat":52.09083,"lon":5.12222}},{"facility":"Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust","status":"RECRUITING","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Kings College Hospital NHS Foundation Trust","status":"RECRUITING","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"University College London","status":"RECRUITING","city":"London","zip":"WC1E 6BT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D000755","term":"Anemia, Sickle Cell"}],"ancestors":[{"id":"D000745","term":"Anemia, Hemolytic, Congenital"},{"id":"D000743","term":"Anemia, Hemolytic"},{"id":"D000740","term":"Anemia"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D006453","term":"Hemoglobinopathies"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07075640","orgStudyIdInfo":{"id":"AG236-C-001"},"organization":{"fullName":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants","officialTitle":"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03-25","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-08-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-11","studyFirstSubmitQcDate":"2025-07-11","studyFirstPostDateStruct":{"date":"2025-07-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-02","lastUpdatePostDateStruct":{"date":"2026-02-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants."},"conditionsModule":{"conditions":["Healthy Participants"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment Group A","type":"EXPERIMENTAL","description":"Participants will receive a single dose of AG-236 at dose level 1 or placebo on Day 1 under fasted conditions.","interventionNames":["Drug: AG-236","Drug: Placebo"]},{"label":"Treatment Group B","type":"EXPERIMENTAL","description":"Participants will receive a single dose of AG-236 at dose level 2 or placebo on Day 1 under fasted conditions.","interventionNames":["Drug: AG-236","Drug: Placebo"]},{"label":"Treatment Group C","type":"EXPERIMENTAL","description":"Participants will receive a single dose of AG-236 at dose level 3 or placebo on Day 1 under fasted conditions.","interventionNames":["Drug: AG-236","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"AG-236","description":"Subcutaneous (SC) Injection","armGroupLabels":["Treatment Group A","Treatment Group B","Treatment Group C"]},{"type":"DRUG","name":"Placebo","description":"SC Injection","armGroupLabels":["Treatment Group A","Treatment Group B","Treatment Group C"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to Study Drug","timeFrame":"Up to Day 57"}],"secondaryOutcomes":[{"measure":"Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Maximum Observed Plasma Concentration (Cmax) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Percentage of Area Under the Concentration-Time Curve due to Extrapolation From the Last Quantifiable Concentration to Infinity (AUC%extrap) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Time to Last Measurable Concentration (tlast) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Time to Reach Maximum Observed Plasma Concentration (tmax) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Terminal Elimination Half-Life (t1/2) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Apparent Total Body Clearance (CL/F) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Apparent Volume of Distribution (Vz/F) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 57"},{"measure":"Amount of Unchanged AG-236 Excreted in Urine From Day 1 to Day 3 (Aet1-t2)","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 3"},{"measure":"Cumulative Amount of Unchanged AG-236 Excreted in Urine (Cum Aeu)","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 3"},{"measure":"Percentage of AG-236 Dose Excreted Unchanged in Urine From Day 1 to Day 3 (fet1-t2)","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 3"},{"measure":"Cumulative Percentage of AG-236 Dose Excreted Unchanged in Urine (Cum fe)","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 3"},{"measure":"Renal Clearance (CLR) of AG-236","timeFrame":"Predose and multiple time points postdose from Day 1 to Day 3"},{"measure":"Change From Baseline in Serum Hepcidin Levels","timeFrame":"Baseline, Days 2, 3, 8, 29, and 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Male or female, of any race, between 18 and 55 years of age, inclusive.\n\n  1. Females must be of nonchildbearing potential.\n  2. Males must agree to use contraception.\n  3. Males must agree not to donate sperm during the study and for 90 days or 5-half-lives of AG-236 in plasma, whichever is longer, after dose administration.\n* Body mass index between 18.0 and 32.0 kilograms per square meter (kg/m2), inclusive.\n* Body weight between 50 and 100 kg, inclusive.\n* In good health, as determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG) and vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \\[eg, suspicion of Gilbert's syndrome based on total and direct bilirubin\\] is not acceptable) at screening and check-in, and from the physical examination at screening, as assessed by the investigator or designee.\n* Able to comprehend and willing to sign the informed consent form (ICF) and abide by the study restrictions.\n\nExclusion Criteria\n\n* Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.\n* History of malignancy, with the exception of adequately treated non-melanomatous skin carcinoma.\n* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator or designee.\n* History or presence of iron deficiency or iron deficiency anemia and/or currently receiving oral or parenteral iron supplementation as treatment for those conditions or deemed high risk of iron deficiency as determined by the investigator.\n\n  1. Males: ferritin \\<30 nanogram per millilitres (ng/mL) and/or transferrin saturation (TSAT): ≤25%.\n  2. Females: ferritin \\<30 ng/mL and/or TSAT: ≤20%.\n* Fever (oral body temperature \\>38°C) or symptomatic viral or bacterial infection within 2 weeks prior to screening; evidence of intestinal infection (such as a participant-reported history of gastrointestinal symptoms \\[eg, nausea, vomiting, diarrhea\\] that are consistent, in the opinion of the investigator, with an acute viral or bacterial process) within 30 days prior to screening.\n* Confirmed systolic blood pressure \\>140 or \\<90 millilitres of mercury (mmHg), diastolic blood pressure \\>90 or \\<50 mmHg, or pulse rate \\>100 or \\<40 beats per minute. If any parameter is out of range, measurements should be repeated twice. Participants will be excluded if the average of the 3 measurements are outside of the corresponding reference range.\n* Clinically significant abnormality, as determined by the investigator, on ECG performed at screening or check-in or any of the following:\n\n  1. QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>450 milliseconds (ms) in males or \\>470 ms in females, confirmed by calculating the mean of the triplicate values obtained\n  2. history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, or family history of long QT syndrome).\n  3. Clinical laboratory values that are outside the normal reference range and are considered clinically significant, as determined by the investigator.\n  4. Clinical laboratory values for hemoglobin (Hb) for males \\<13.8 grams per decilitres g/dL and females \\<12.1 g/dL.\n  5. Clinical laboratory values for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and/or total bilirubin \\>1 × upper limit of normal (ULN).\n* Participants will be excluded if a single repeat confirms the result.\n* Positive hepatitis panel and/or positive human immunodeficiency virus test.\n* Participants whose results are compatible with prior immunization may be included.\n* Clinical laboratory value for partial thromboplastin time (PTT) \\>1 × ULN and/or International Normalized Ratio (INR) \\>1.2. Participants will be excluded if a single repeat confirms the result.\n* Administration of any vaccine within 30 days prior to dosing.\n* Use or intend to use during the study duration any prescription medications/products, including hormone replacement therapy, within 28 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.\n* Use or intend to use during the study duration any slow-release medications/products considered to still be active within 28 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.\n* Use or intend to use during the study duration any nonprescription medications/products including vitamins (including iron-containing multivitamins), minerals, biotin supplements, recreational drugs, or phytotherapeutic/herbal/plant-derived preparations within 28 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.\n* Participation in a clinical study involving administration of an IMP (new chemical entity) in the past 30 days or 5 half-lives of that drug (if known) prior to dosing, whichever is longer.\n* Have previously completed or withdrawn from this study or any other study investigating AG-236 and have previously received AG-236.\n* Alcohol consumption of \\>14 units per week for males and females. One unit of alcohol equals 12 ounces (oz) (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.\n* Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.\n* History of alcoholism or drug/chemical abuse within 2 years prior to check-in.\n* Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.\n* Have special dietary restrictions or inability to consume standard meals as required in the study.\n* Receipt of blood products within 2 months prior to check in.\n* Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening.\n* Poor peripheral venous access.\n* Participants who, in the opinion of the investigator or designee, should not participate in this study.\n* Increased risk of thrombosis, as determined by the investigator or designee.\n* Clinical laboratory value for homocysteine \\>1 × ULN.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Agios Medical Affairs","role":"CONTACT","phone":"833-228-8474","email":"medinfo@agios.com"}],"locations":[{"facility":"Fortrea Clinical Research Unit Inc.","status":"RECRUITING","city":"Madison","state":"Wisconsin","zip":"53704","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04278781","orgStudyIdInfo":{"id":"19-393"},"organization":{"fullName":"Memorial Sloan Kettering Cancer Center","class":"OTHER"},"briefTitle":"AG-120 in People With IDH1 Mutant Chondrosarcoma","officialTitle":"Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","startDateStruct":{"date":"2020-03-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-02-18","studyFirstSubmitQcDate":"2020-02-18","studyFirstPostDateStruct":{"date":"2020-02-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-22","lastUpdatePostDateStruct":{"date":"2025-10-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Memorial Sloan Kettering Cancer Center","class":"OTHER"},"collaborators":[{"name":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation."},"conditionsModule":{"conditions":["Chondrosarcoma","Chondrosarcoma, Grade 2","Chondrosarcoma, Grade 3","IDH1 Gene Mutation"],"keywords":["Chondrosarcoma","Chondrosarcoma, Grade 2","Chondrosarcoma, Grade 3","IDH1 Gene Mutation","IDH1 Mutant Chondrosarcoma","AG-120","locally advanced chondrosarcoma","metastatic chondrosarcoma","Memorial Sloan Kettering Cancer Center","19-393"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":6,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Chondrosarcoma","type":"EXPERIMENTAL","description":"Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma","interventionNames":["Drug: AG-120"]}],"interventions":[{"type":"DRUG","name":"AG-120","description":"AG-120 500 mg orally once daily days 1-28 of a 28-day cycle","armGroupLabels":["Chondrosarcoma"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression free survival","description":"Progression free survival includes both disease progression (as defined by RECIST 1.1) and death from any cause","timeFrame":"16 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be \\>/= 18 years of age\n* Have a histological diagnosis (fresh or archived tumor biopsy sample) of locally advanced/metastatic or recurrent operable chondrosarcoma (conventional grade 2 or 3 only) confirmed by central pathology review\n\n  * Patients with low grade (grade 1) and dedifferentiated chondrosarcoma are ineligible\n  * Patients with biopsy proven low grade (grade 1) pelvic chondrosarcoma are ineligible unless they have radiological imaging consistent with higher grade disease in which case they will be deemed potentially eligible. In such cases the pre-treatment biopsy should be taken where feasible from the area of presumed higher-grade disease to confirm grade 2 or 3 disease to confirm eligibility\n  * Patients without confirmation of grade 2 or 3 disease will not be eligible for the study unless in the case where radiology features are consistent with high grade disease but a biopsy confirmation of this is not technically feasible. Such cases should be discussed with the principal investigator before enrollment onto the study\n* Have a documented IDH1 gene mutation (from a fresh tumor biopsy or from archived tumor tissue) confirmed by a CLIA approved laboratory.\n* Have an ECOG OS score of 0 to 2.\n* Have expected survival of \\>/= 4 months.\n* Have at least one measurable lesion as defined by RECIST 1.1, subjected who have received prior local therapy are eligible provided the measurable disease falls outside of the treatment field or within the field and has shown \\>/=20% growth in size since post-treatment assessment.\n* Have documented radiographic disease progression within the preceding 4 months before study entry (date ICF signed).\n\nHave recovered from toxicities associated with prior anti-cancer therapy to baseline unless stabilized under medical management (see washout time from different therapies in Exclusion Criteria section).\n\n* Have adequate bone marrow functions as evidenced by:\n\n  * Absolute neutrophil count \\>/=1,500/mm\\^3 or 100 x 10\\^9/L.\n  * Hemoglobin \\>/=8/dL.\n  * Platelets \\>/=100,000/mm\\^3 or 100 x 10\\^9/L.\n* Have adequate hepatic function as evidenced by:\n\n  * Serum total bilirubin \\</=2 x upper limit of normal (ULN), unless considered due to Gilbert's disease.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\</=5 x ULN.\n* Have adequate renal function as evidenced by:\n\n  * Serum creatinine \\<1.5 x ULN OR\n  * creatinine clearance \\>/= 50ml/min based on the cockcroft-gault glomerular filtration rate (GFR) estimation:\n  * (140 Age) x (weight in kg) x (0.85 if female)/72 x serum creatinine\n* Be able to understand and willing to sign the informed consent form and to comply with scheduled visits, treatment plans, procedures and laboratory tests, including serial peripheral blood sampling and urine sampling, during the study. A legally authorized representative may consent on behalf of a subject who is otherwise unable to provide informed consent if acceptable to and approved by the site's Institutional Review Board (IRB)\n* Be able to swallow oral medication.\n* Female subjects with reproductive potential must have a negative serum or urine pregnancy test prior to the start of therapy, or a confirmation from an obstetrician in case of equivocal serum pregnancy results. Females of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated) for at least 24 consecutive months (i.e., have not had menses at any time in the preceding 24 consecutive months). Women of reproductive potential, as well as fertile men and their partners who are female with reproductive potential, must agree to use 2 effective forms of contraception (including at least 1 barrier form) from the time of giving informed consent throughout the study and for 90 days (both females and males) following the last dose of study drug. Effective forms of contraception are defined as hormonal oral contraceptive, injectables, patches, intrauterine devices, intrauterine hormone-releasing systems bilateral tubal ligation, condoms with spermicide, or male partner sterilization.\n\nExclusion Criteria:\n\n* Received a prior IDH1 inhibitor.\n* Received systemic anticancer therapy or an investigational agent \\< 3 week prior to the Day 1 (washout from prior immune based anticancer therapy is 4 weeks).\n* Received radiotherapy or other local intervention to metastatic sites of disease \\<2 weeks prior to Day 1.\n* Underwent major surgery within 4 weeks of Day 1 or have not recovered from clinically significant post-surgery toxicities.\n* Have known symptomatic brain metastasis requiring steroids. Subject with previously diagnosed brain metastases are eligible if they completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and have a radiographically stable disease for a least 3 months prior to study entry.\n\n  \\*Note: up to 10mg per day of prednisolone or equivalent will be allowed,\n* Has another concurrent active cancer requiring therapeutic intervention.\n* Are pregnant or breastfeeding.\n* Are taking known strong CYP3A4 inducers or sensitive CYP3A4 substrate medications with a narrow therapeutic window unless they can be transferred to other medication within \\>/=5 half-lives prior to dosing\n* Are taking p-glycoprotein (P-gp) transporter-sensitive substrate medications with a narrow therapeutic window, unless they can be transferred to other medications within \\>/= half-lives prior to dosing, or unless the medications can be properly monitored during the study.\n* Have an active infection requiring systemic anti-infective therapy or with an unexplained fever \\> 38.5 degrees C within 7 days of Day 1 (at the discretion of the investigator, subjects with tumor fever may be enrolled).\n* Have any known hypersensitivity to any components of AG-120.\n* Have significant active cardiac disease within 6 months prior to the start of study treatment, including New York Heart Association Class II or IV congestive heart failure: myocardial infraction: unstable angina; and/or stroke.\n* Have LVEP \\<40% by ECHO and/or MUGA scan obtained within 28 days prior to the start of the study treatment.\n* Have a heart-rate corrected QT interval \\[using Frederica's Formula\\] (QTcF) \\>/=450msec or other factor that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome). Bundle branch block and prolonged QTcF interval are permitted with approval of the principal investigator.\n* Are taking medications known to prolong the QT interval, unless they can have transferred to other medications within \\>/= half-lives prior to dosing, or unless the medications can be properly monitored during the study (If equivalent medication is not available, QTcF should be closely monitored).\n* Have known active hepatitis B (HBV) or hepatitis C (HCV) infections, known positive human immunodeficiency virus (HIV) antibody results, or acquired immunodeficiency syndrome (AIDS) related illness. Subjects with a sustained viral response to HCV or immunity to prior HBV infection will be permitted. Subjects with chronic HBV that is adequately suppressed per institutional practice will be permitted.\n* Have any other acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or a laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n* Have known active inflammatory gastrointestinal disease, previous gastric resection, or lap band dysphagia, short bowel syndrome, gastroparesis or other conditions that limit ingestion or gastrointestinal absorption of drugs administered orally.\n* Has a known medical history of progressive multifocal leukoencephalopathy (PML)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ciara M Kelly, MBBCh, BAO","affiliation":"Memorial Sloan Kettering Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Johns Hopkins Hospital (Data Collection Only)","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Columbia University (Specimen Analysis Only)","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"The Ohio State University (Data Collection Only)","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"MD Anderson Cancer Center (Data Collection Only)","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"references":[{"pmid":"38446419","type":"DERIVED","citation":"Ramsey DC. CORR Insights(R): Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone? Clin Orthop Relat Res. 2024 Jun 1;482(6):957-959. doi: 10.1097/CORR.0000000000003019. Epub 2024 Mar 6. No abstract available."}],"seeAlsoLinks":[{"label":"Memorial Sloan Kettering Cancer Center","url":"http://www.mskcc.org"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2022-05-02","uploadDate":"2025-08-26T11:59","filename":"ICF_000.pdf","size":823108}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D002813","term":"Chondrosarcoma"},{"id":"D008224","term":"Lymphoma, Follicular"}],"ancestors":[{"id":"D009372","term":"Neoplasms, Connective Tissue"},{"id":"D018204","term":"Neoplasms, Connective and Soft Tissue"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D012509","term":"Sarcoma"},{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D008223","term":"Lymphoma"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000627630","term":"ivosidenib"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07055243","orgStudyIdInfo":{"id":"OZUHN-025"},"organization":{"fullName":"University Health Network, Toronto","class":"OTHER"},"briefTitle":"To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.","officialTitle":"Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies - Canada (SATISFY-CA)","acronym":"SATISFY-CA"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-06-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-04-17","studyFirstSubmitQcDate":"2025-07-03","studyFirstPostDateStruct":{"date":"2025-07-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-03","lastUpdatePostDateStruct":{"date":"2025-07-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University Health Network, Toronto","class":"OTHER"},"collaborators":[{"name":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering week. Data collected from Princes Margaret will be incorporated to the main study conducted in EU for analysis. Overall, approximately 25 patients are expected to be enrolled: Approximately 16 patients at sites in the EU and approximately 9 patients in Canada.","detailedDescription":"This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII. Gobal target is 25 patients. 9 patients from UHN, Canada will be enrolled to the study. All enrolled patients will receive the study drug Mitapivat. All eligible subjects who enter the Dose Escalation Period will receive an initial dose of 50 mg mitapivat BID. After 4 weeks dose will be increased from 50 mg BID to 100 mg BID unless dose limiting side effects have occurred or maximum allowed Hb levels have been reached. The maximum dosage is 100 mg BID, for patients in which no dosage limiting side effects have occurred and maximum allowed hemoglobin levels have not been reached.\n\nMaximal study duration per subject is screening period (≤50 days) + 57 weeks on study drug:\n\n* 8 weeks Dose Escalation Period\n* 24 Fixed Dose Period 1\n* 24 Fixed Dose Period 2\n* 1 week Dose Taper Dose reduction is allowed at any time during both the Dose Escalation Period and the Fixed Dose Extension Period. In cases, where 50 mg BID provides dose limiting side effect(s), subjects can be offered dose reduction to 20 mg BID. If 20 mg BID provides dose limiting side effect(s), subjects can be further dose reduced to 5 mg BID. Subjects receiving dosage of \\<50mg BID are allowed to continue in the study.\n\nPhysical exam, ECG, vital signs, Dexa scan, MRI scan, safety blood work will be carried out thorough out the study. Patients will be asked to complete 2 questionnaires in a online web browser during the study visits at the clinic."},"conditionsModule":{"conditions":["Anemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":9,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Mitapivat","type":"EXPERIMENTAL","description":"All patients will receive the drug Mitapivat","interventionNames":["Drug: Mitapivat"]}],"interventions":[{"type":"DRUG","name":"Mitapivat","description":"Mitapivat will be given to adult patients with erythrocyte membranopathies","armGroupLabels":["Mitapivat"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To evaluate safety of mitapivat","description":"Type, incidence, severity and relationship of mitapivat to AE and SAE","timeFrame":"61 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female with RBC membranopathy or congenital dyserythropoietic anemia type II (CDAII). Diagnosis must be supported genetically by a ACMG class 3 (VUS), 4 or 5 variant.\n2. Age ≥18 years.\n3. Average hemoglobin (Hb) concentration (average of at least 2 Hb measurements separated by a minimum of 7 days the during screening period) must be less than 13.0 g/dL for males and 11.0 g/dL for females. Patients with average Hb \\>10.0 g/dL for males and females must meet at least one of the following additional criteria:\n\n   1. Splenomegaly (length ≥12.5 cm)\n   2. Fatigue attributed to hemolysis\n   3. Active hemolysis as evaluated by one or more of the following: haptoglobin, bilirubin, LDH, reticulocytes\n4. Subjects must start or continue taking at least the equivalent of daily 0.8 mg oral folic acid for the duration of the study.\n5. Have adequate organ function, as defined by:\n\n   1. Serum aspartate aminotransferase (AST) ≤2.5 × ULN (unless the increased AST is assessed by the Investigator as due to hemolysis and/or hepatic iron deposition) and alanine aminotransferase (ALT) ≤2.5 × ULN.\n   2. Normal or elevated levels of serum bilirubin. In subjects with serum bilirubin \\> ULN, the elevation must be attributed to hemolysis with or without Gilbert's syndrome and must not be associated with choledocholithiasis, cholecystitis, biliary obstruction, or hepatocellular disease Elevated bilirubin attributed to hemolysis with or without Gilbert's syndrome is not exclusionary.\n   3. Estimated glomerular filtration rate ≥45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration creatinine\n6. Be willing and able to give written informed consent and to comply to all study procedures for the duration of the study.\n7. For women of reproductive potential, have a negative urine or serum pregnancy test during the Screening Period (Day -50 to Day -1). Women of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion; or who have not been naturally postmenopausal (i.e. who have not menstruated at all for at least the preceding 12 months prior to signing informed consent), or has a known diagnosis of hypogonadotropic hypogonadism.\n8. For women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use a highly effective method of contraception. A highly effective form of contraception is defined as combined (estrogen and progestin containing) hormonal contraceptives (oral, intravaginal, or transdermal) associated with inhibition of ovulation; progestin-only hormonal contraceptives (oral, injectable, or implantable) associated with inhibition of ovulation; intrauterine device; intrauterine hormone releasing system; bilateral tube occlusion; or vasectomized partner. Women of reproductive potential using hormonal contraception as a highly effective form of contraception must also utilize an acceptable barrier method while enrolled in the study and for at least 28 days after their last dose of study drug. An acceptable barrier method includes male or female condoms with or without spermicide, and cervical cap, diaphragm, or sponge with spermicide.\n\nExclusion Criteria:\n\n1. Known history of pyruvate kinase deficiency (decreased PK activity or two pathogenic PKLR alleles). PK activity and PKLR testing is not required.\n2. Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic or preventive transfusion), defined as more than 5 transfusion episodes in the 12-month period up to the first day of study treatment, and/or have received a transfusion within the past 3 months prior to the first day of study treatment.\n3. Have a significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound interpretation of the study data. Such significant medical conditions include, but are not limited to:\n\n   1. Poorly controlled hypertension (defined as systolic blood pressure \\>150 mm Hg or diastolic blood pressure \\>90 mm Hg) refractory to medical management.\n   2. Any history of congestive heart failure; myocardial infarction or unstable angina pectoris; hemorrhagic, embolic, or thrombotic stroke; or recent (\\< 6 months prior to signing informed consent) deep venous thrombosis; or pulmonary or arterial embolism.\n   3. Cardiac dysrhythmias judged as clinically significant by the Investigator.\n   4. Clinically symptomatic cholelithiasis or cholecystitis. Prior cholecystectomy is not exclusionary. Subjects with symptomatic cholelithiasis or cholecystitis may be rescreened once the disorder has been treated and clinical symptoms have resolved.\n   5. History of drug-induced cholestatic hepatitis.\n   6. Severe iron overload as evaluated by the Investigator. This includes cardiac (eg, clinically significant impaired left ventricular ejection fraction) or hepatic (eg, fibrosis, cirrhosis) dysfunction.\n   7. Have a diagnosis of any other congenital or acquired blood disorder or any other hemolytic process, except mild allo-immunization, as a consequence of transfusion therapy.\n\n   g. Positive test for HBsAg or HCVAb with signs of active hepatitis B or C virus infection. Subjects with hepatitis C may be rescreened after receiving appropriate hepatitis C treatment.\n\n   i. Positive test for HIV-1 or -2 antibodies. j. Active infection requiring the use of parenteral antimicrobial agents or Grade ≥3 in severity (per NCI CTCAE) within 2 months prior to the first dose of study treatment.\n\n   k. Diabetes mellitus judged to be under poor control by the Investigator or requiring \\>3 antidiabetic agents, including insulin (all insulins are considered 1 agent); use of insulin per se is not exclusionary.\n\n   l. History of any primary malignancy, with the exception of: curatively treated non-melanomatous skin cancer; curatively treated cervical or breast carcinoma in situ; or other primary tumor treated with curative intent, no known active disease present, and no treatment administered during the last 3 years.\n\n   m. Unstable extramedullary hematopoiesis that could pose a risk of imminent neurologic compromise.\n\n   n. Severe hepatic issues such as liver fibrosis (F3 or worse), significant cirrhosis or non-alcoholic fatty liver disease (NASH).\n\n   o. Current or recent history of psychiatric disorder that, in the opinion of the Investigator, could compromise the ability of the subject to cooperate with study visits and procedures.\n\n   p. Alcohol use disorder.\n\n4\\. Are currently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo. Participation in registry studies is allowed.\n\n5\\. Have exposure to any investigational drug, device, or procedure within 5 half-lives or 3 months (whichever is longer) to the first dose of study treatment.\n\n6\\. Have had any prior treatment with a pyruvate kinase activator.\n\n7\\. Have a prior bone marrow or stem cell transplant.\n\n8\\. Are currently pregnant or breastfeeding or planning to become pregnant during the course of the study.\n\n9\\. Have a history of major surgery within 6 months prior to signing informed consent. Note that procedures such as laparoscopic gallbladder surgery are not considered major in this context.\n\n10\\. Are currently receiving medications that are strong inhibitors of CYP3A4 and strong inducers of CYP3A4 that have not been stopped for a duration of at least 5 days or a timeframe equivalent to 5 half-lives (whichever is longer) prior to the first dose of study treatment.\n\n11\\. Are currently receiving hematopoietic stimulating agents (eg, erythropoietins, granulocyte colony stimulating factors, thrombopoietins) that have not been stopped for a duration of at least 28 days prior to the first dose of study treatment.\n\n12\\. Known allergy to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, and mannitol) or history of acute allergic reaction to drugs characterized by acute hemolytic anemia, drug-induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis, or other serious clinical manifestations.\n\n13\\. For men and women of reproductive potential: unwillingness to be abstinent or use double anticonception during the trial period.\n\n14\\. Are currently receiving herbal or dietary supplements that have not been stable in dose and preparation for \\>8 weeks prior to randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Kevin Kuo, MD","role":"CONTACT","phone":"416-340-5233","email":"Kevin.Kuo@uhn.ca"}],"locations":[{"facility":"University Health Network (UHN)","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M5G 2C4","country":"Canada","contacts":[{"name":"Kevin Kuo, MD","role":"CONTACT","phone":"416-340-5233","email":"Kevin.Kuo@uhn.ca"}],"geoPoint":{"lat":43.70643,"lon":-79.39864}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D000740","term":"Anemia"}],"ancestors":[{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000634504","term":"mitapivat"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04902833","orgStudyIdInfo":{"id":"21-187"},"organization":{"fullName":"Massachusetts General Hospital","class":"OTHER"},"briefTitle":"Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms","officialTitle":"Characterization Of Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-02-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-05-21","studyFirstSubmitQcDate":"2021-05-21","studyFirstPostDateStruct":{"date":"2021-05-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-14","lastUpdatePostDateStruct":{"date":"2025-11-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hanny Al-Samkari, MD","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Massachusetts General Hospital"},"leadSponsor":{"name":"Massachusetts General Hospital","class":"OTHER"},"collaborators":[{"name":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.","detailedDescription":"This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.\n\n* Red cell pyruvate kinase enzyme activity and next-generation sequencing (NGS) hereditary hemolytic anemia panels will be performed on samples from all recruited participants.\n* The study will recruit patients to two separate cohorts.\n\n  * Cohort 1 will recruit approximately 75 anemic (Hgb \\<11.0 g/dL) MDS participants without overt clinical evidence of hemolysis.\n  * Cohort 2 will recruit approximately 25 participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia\n* Participation in the study involves a single blood draw. Basic information about the participant's blood disorder will also be collected.\n\nIt is expected that about 100 people will take part in this research study"},"conditionsModule":{"conditions":["Pyruvate Kinase Deficiency","Pyruvate Kinase Deficiency Anemia","Hereditary Hemolytic Anemia","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasm","Clonal Myeloid Neoplasm","Myeloproliferative Neoplasm","Acute Myeloid Leukemia","Clonal Cytopenia of Undetermined Significance","Other Clonal Myeloid Neoplasm","Unexplained Coombs-negative Non-immune Hemolytic Anemia"],"keywords":["Pyruvate Kinase Deficiency","Pyruvate Kinase Deficiency Anemia","Hereditary Hemolytic Anemia","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasm","Clonal myeloid neoplasm","Myeloproliferative Neoplasm","Acute Myeloid Leukemia","Clonal Cytopenia of Undetermined Significance","Other clonal myeloid neoplasm","Unexplained Coombs-negative non-immune hemolytic anemia"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort I","description":"Approximately 75 anemic (Hgb \\<11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis.\n\n\\- Single Blood Draw","interventionNames":["Procedure: Blood Draw"]},{"label":"Cohort 2","description":"25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia\n\n-Single Blood Draw","interventionNames":["Procedure: Blood Draw"]}],"interventions":[{"type":"PROCEDURE","name":"Blood Draw","description":"Blood specimen 2-4 teaspoons","armGroupLabels":["Cohort 2","Cohort I"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall prevalence of possible or likely acquired pyruvate kinase deficiency","description":"defined by PK enzyme activity or PK:HK ratio \\>1 SD below the control mean (healthy subject mean) as measured by enzyme assay, or potentially pathogenic mutations in the PKLR gene as found on PKLR sequencing","timeFrame":"Day 1"}],"secondaryOutcomes":[{"measure":"Overall prevalence of definite acquired pyruvate kinase deficiency","description":"Defined by PK enzyme activity below normal (or a PK:HK ratio \\<8.7) as measured by enzyme assay, or known pathogenic mutations in the PKLR gene as found on PKLR sequencing","timeFrame":"Day 1"},{"measure":"Red cell pyruvate kinase enzyme activity","description":"Red cell pyruvate kinase enzyme activity in patients not receiving red cell transfusion in the 60 days prior to blood draw","timeFrame":"60 days"},{"measure":"Red cell pyruvate kinase","description":"hexokinase enzyme activity ratio in patients not receiving red cell transfusion in the 60 days prior to blood draw","timeFrame":"60 Day"},{"measure":"Somatic mutations in PKLR (and other genes associated with acquired PKD) detected in the hematopoietic clone","timeFrame":"Day 1"},{"measure":"Somatic mutations in other genes associated with hemolytic anemia detected in the hematopoietic clone","timeFrame":"Day 1"},{"measure":"Characterization of pyruvate kinase-related red cell metabolites (ATP, 2,3-DPG) and pyruvate kinase-R protein in patients with clonal myeloid disorders","timeFrame":"Day 1"},{"measure":"Impact of pyruvate kinase activators on PK activity in vitro","timeFrame":"Day 1"}],"otherOutcomes":[{"measure":"Characterization of other possible factors involved in acquired PKD, including acquired epigenetic or gene expression factors","timeFrame":"Day 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cohort 1\n\n  * Capable and willing to provide informed consent for participation in the study.\n  * Diagnosis of clonal cytopenia of undetermined significance (CCUS), myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN syndrome) according to 2016 World Health Organization (WHO) classification system.\n  * Anemia secondary to underlying clonal cytopenia of undetermined significance (CCUS), MDS or MDS/MPN syndrome, defined as a hemoglobin \\<11.0 g/dL measured within 30 days of study enrollment. Anemia should not be related to nutritional deficiency (such as iron, cobalamin, folate, or copper deficiencies), peripheral immune or non-immune hemolysis, or renal disease, in the opinion of the investigator.\n  * Age \\>18 years.\n* Cohort 2\n\n  * Capable and willing to provide informed consent for participation in the study.\n  * Diagnosis of a clonal myeloid neoplasm, such as MDS, MDS/MPN syndrome, myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), clonal cytopenia of undetermined significance (CCUS), or other clonal myeloid neoplasm according to 2016 World Health Organization (WHO) classification system.\n  * A diagnosis of an otherwise unexplained Coombs-negative non-immune hemolytic anemia, according to the clinical judgement of the investigator. Some form of objective laboratory evidence must be present, including one or more of the following: negative direct antiglobulin (Coombs) test, reduced haptoglobin, elevated indirect bilirubin, elevated lactate dehydrogenase, elevated aspartate aminotransferase, or compatible findings on peripheral blood film. Results of all of these tests are not required to satisfy this criterion.\n  * Age \\>18 years.\n\nExclusion Criteria:\n\n* Cohort 1\n\n  * Receipt of red cell transfusion within 60 days of study enrollment.\n  * Have a known untreated nutritional anemia or acquired disorder resulting in hemolysis, such as paroxysmal nocturnal hemoglobinuria (PNH). A known hereditary anemia (such as thalassemia trait) is not exclusionary if the patient's baseline hemoglobin has worsened significantly (in the opinion of the investigator) after development and diagnosis of MDS.\n* Cohort 2\n\n  * Have a known hereditary anemic disorder, such as thalassemia, sickle cell disease, or hereditary enzyme deficiency, with the exception of hereditary X-linked glucose-6-phosphate dehydrogenase deficiency known not to cause chronic baseline hemolysis. Testing for these diagnoses is not required unless deemed clinically necessary.\n  * Have a known untreated nutritional anemia or acquired disorder resulting in hemolysis, such as paroxysmal nocturnal hemoglobinuria (PNH).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Cohort 1 will recruit approximately 50 anemic (Hgb \\<11.0 g/dL) MDS patients without overt clinical evidence of hemolysis. Cohort 2 will recruit approximately 50 patients with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Hanny Al-Samkari, MD","affiliation":"Massachusetts General Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"Data can be shared no earlier than 1 year following the date of publication","accessCriteria":"Contact the Partners Innovations team at http://www.partners.org/innovation"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"C564858","term":"Pyruvate Kinase Deficiency of Red Cells"},{"id":"D000745","term":"Anemia, Hemolytic, Congenital"},{"id":"D009190","term":"Myelodysplastic Syndromes"},{"id":"D054437","term":"Myelodysplastic-Myeloproliferative Diseases"},{"id":"D009196","term":"Myeloproliferative Disorders"},{"id":"D015470","term":"Leukemia, Myeloid, Acute"}],"ancestors":[{"id":"D000743","term":"Anemia, Hemolytic"},{"id":"D000740","term":"Anemia"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D001855","term":"Bone Marrow Diseases"},{"id":"D007951","term":"Leukemia, Myeloid"},{"id":"D007938","term":"Leukemia"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D001800","term":"Blood Specimen Collection"}],"ancestors":[{"id":"D013048","term":"Specimen Handling"},{"id":"D019411","term":"Clinical Laboratory Techniques"},{"id":"D019937","term":"Diagnostic Techniques and Procedures"},{"id":"D003933","term":"Diagnosis"},{"id":"D011677","term":"Punctures"},{"id":"D013514","term":"Surgical Procedures, Operative"},{"id":"D008919","term":"Investigative Techniques"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05490446","orgStudyIdInfo":{"id":"AG946-C-002"},"secondaryIdInfos":[{"id":"2022-500609-42-00","type":"OTHER","domain":"EU-CTR"}],"organization":{"fullName":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)","officialTitle":"A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2029-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-07-26","studyFirstSubmitQcDate":"2022-08-04","studyFirstPostDateStruct":{"date":"2022-08-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-27","lastUpdatePostDateStruct":{"date":"2026-01-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Agios Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b."},"conditionsModule":{"conditions":["Myelodysplastic Syndromes"],"keywords":["Anemia","Lower-Risk Myelodysplastic Syndromes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":87,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Core Period: Phase 2a - Tebapivat 5 mg","type":"EXPERIMENTAL","description":"Participants will receive 5 milligrams (mg) tebapivat orally, once daily for up to 16 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.","interventionNames":["Drug: Tebapivat"]},{"label":"Core Period: Phase 2b - Tebapivat 10 mg","type":"EXPERIMENTAL","description":"Participants will receive 10 mg tebapivat, orally, once daily for up to 24 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.","interventionNames":["Drug: Tebapivat"]},{"label":"Core Period: Phase 2b - Tebapivat 15 mg","type":"EXPERIMENTAL","description":"Participants will receive 15 mg tebapivat, orally, once daily for up to 24 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.","interventionNames":["Drug: Tebapivat"]},{"label":"Core Period: Phase 2b - Tebapivat 20 mg","type":"EXPERIMENTAL","description":"Participants will receive 20 mg tebapivat, orally, once daily for up to 24 weeks. At the discretion of the investigator, participants who complete the Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.","interventionNames":["Drug: Tebapivat"]}],"interventions":[{"type":"DRUG","name":"Tebapivat","description":"Tebapivat Tablet","armGroupLabels":["Core Period: Phase 2a - Tebapivat 5 mg","Core Period: Phase 2b - Tebapivat 10 mg","Core Period: Phase 2b - Tebapivat 15 mg","Core Period: Phase 2b - Tebapivat 20 mg"],"otherNames":["AG-946"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 2a: Proportion of Participants With Hemoglobin (Hb) Response","description":"Hb response is defined as a ≥1.5-grams per deciliter (g/dL) increase from baseline in the average Hb concentration from Week 8 through Week 16.","timeFrame":"Baseline, Week 8 through Week 16"},{"measure":"Phase 2a: Proportion of Participants With Transfusion Independence During the Core Period","description":"Transfusion Independence is defined as transfusion-free for ≥8 consecutive weeks during the Core Period (participants With Low Transfusion Burden \\[LTB\\] only).","timeFrame":"Up to 16 weeks"},{"measure":"Phase 2b: Proportion of Participants With Transfusion Independence","description":"Transfusion independence, defined as transfusion-free for ≥8 consecutive weeks (TI8) during the Core Period.","timeFrame":"Up to 24 weeks"}],"secondaryOutcomes":[{"measure":"Phase 2a: Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation During the Core Period","description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An SAE is any AE or suspected adverse reaction that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly/birth defect, or is considered an important medical event.","timeFrame":"Up to 16 weeks"},{"measure":"Phase 2a: Proportion of Participants With Laboratory Abnormalities During the Core Period","timeFrame":"Up to 16 weeks"},{"measure":"Phase 2a: Proportion of Participants With Hb 1.0+ Response","description":"Hb 1.0+ response is defined as a ≥1.0-g/dL increase from baseline in the average Hb concentration from Week 8 through Week 16","timeFrame":"Baseline, Week 8 through Week 16"},{"measure":"Phase 2a: Change From Baseline in Hb Concentration During the Core Period","timeFrame":"Baseline up to 16 weeks"},{"measure":"Phase 2a: Proportion of Participants With ≥1.5-g/dL increase From Baseline in the Hb Concentration at ≥2 Consecutive Time Points From Week 8 through Week 16","timeFrame":"Baseline, Week 8 through Week 16"},{"measure":"Phase 2a: Change from Baseline in Total Transfused Red Blood Cell (RBC) Units During the Core Period","timeFrame":"Baseline up to 16 weeks"},{"measure":"Phase 2a: Proportion of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥8 Consecutive Weeks During the Core Period Compared With Baseline","timeFrame":"Baseline up to 16 weeks"},{"measure":"Phase 2a: Plasma Concentration of Tebapivat During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Maximum (Peak) Concentration (Cmax) of Tebapivat During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Time to Cmax (tmax) of Tebapivat During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Area Under the Concentration-time Curve From 0 to t Hours (AUC0-t) of Tebapivat During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval (AUC0-τ) of Tebapivat During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Apparent Terminal Elimination Half-life (t½) of Tebapivat During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Whole Blood Concentrations of 2,3-diphosphoglycerate (2,3-DPG) During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2a: Whole Blood Concentrations of Adenosine Triphosphate (ATP) During the Core Period","timeFrame":"Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)"},{"measure":"Phase 2b: Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation During the Core Period","description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An SAE is any AE or suspected adverse reaction that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly/birth defect, or is considered an important medical event.","timeFrame":"Up to 24 weeks"},{"measure":"Phase 2b: Proportion of Participants With Laboratory Abnormalities During the Core Period","timeFrame":"Up to 24 weeks"},{"measure":"Phase 2b: Change From Baseline in Hb Concentration During the Core Period","timeFrame":"Baseline up to 24 weeks"},{"measure":"Phase 2b: Change From Baseline in Total Transfused RBC Units From Week 8 Through Week 24","timeFrame":"Baseline, Week 8 through Week 24"},{"measure":"Phase 2b: Proportion of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥8 Consecutive Weeks During the Core Period Compared With Baseline","timeFrame":"Baseline up to 24 weeks"},{"measure":"Phase 2b: Time to First TI8 During the Core Period","timeFrame":"Baseline up to 24 weeks"},{"measure":"Phase 2b: Proportion of Participants Who Become Transfusion-free for ≥12 Consecutive Weeks (TI12) During the Core Period","timeFrame":"Up to 24 weeks"},{"measure":"Phase 2b: Proportion of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥12 Consecutive Weeks During the Core Period Compared With Baseline","timeFrame":"Baseline up to 24 weeks"},{"measure":"Phase 2b: Time to First TI12 During the Core Period","timeFrame":"Baseline up to 24 weeks"},{"measure":"Phase 2b: Duration of Transfusion Independence (TI)","description":"The duration of TI will be calculated as the number of days in the longest transfusion-free period starting on or after the start of study treatment through the end of the Core Period.","timeFrame":"Baseline up to 24 weeks"},{"measure":"Phase 2b: Plasma Concentration of Tebapivat During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Maximum (Peak) Concentration (Cmax) of Tebapivat During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Time to Cmax (tmax) of Tebapivat During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Area Under the Concentration-time Curve From 0 to t Hours (AUC0-t) of Tebapivat During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval (AUC0-τ) of Tebapivat During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Apparent Terminal Elimination Half-life (t½) of Tebapivat During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Whole Blood Concentrations of 2,3-diphosphoglycerate (2,3-DPG) During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"},{"measure":"Phase 2b: Whole Blood Concentrations of Adenosine Triphosphate (ATP) During the Core Period","timeFrame":"Predose and multiple time points post dose from Day 1 up to Week 20"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPhase 2a\n\n1. At least 18 years of age at the time of providing informed consent;\n2. Documented diagnosis of myelodysplastic syndromes (MDS) according to World Health Organization (WHO) classification (Arber et al, 2016), that meets Revised International Prognostic Scoring System (IPSS-R) classification of lower-risk disease (risk score: ≤3.5) and \\<5% blasts as determined by the participant's bone marrow biopsy/aspirate during the Screening Period;\n3. Nontransfused or with low transfusion burden (LTB), based on transfusion history from the participant's medical record, according to revised International Working Group (IWG) 2018 criteria:\n\n   * Nontransfused (NTD): \\<3 red blood cell (RBC) units in the 16-week period before administration of the first dose of study drug and no transfusions in the 8-week period before administration of the first dose of study drug, or\n   * LTB: 3 to 7 RBC units in the 16-week period before administration of the first dose of study drug and \\<4 RBC units in the 8-week period before administration of the first dose of study drug;\n4. A hemoglobin (Hb) concentration \\<11.0 grams per deciliter (g/dL) during the 4-week Screening Period;\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2;\n6. If taking iron chelation therapy, the iron chelation therapy dose must have been stable and started ≥56 days before administration of the first dose of study drug;\n7. Women of childbearing potential (WOCBP) must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use a highly effective method of contraception from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug; if the highly effective method of contraception is hormonal contraception, then an acceptable barrier method must also be used. Men with partners who are WOCBP must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use a condom from the time of providing informed consent throughout the study and for 28 days after the last dose of study drug;\n8. Written informed consent from the participant before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.\n\nPhase 2b\n\n1. At least 18 years of age at the time of providing informed consent;\n2. Documented diagnosis of MDS according to WHO classification (Arber et al, 2016), that meets IPSS-R classification of lower-risk disease (risk score: ≤3.5) and \\<5% blasts as determined by the participant's bone marrow biopsy/aspirate during the Screening Period;\n3. With LTB, or high transfusion burden (HTB), based on transfusion history from the participant's medical record, according to revised IWG 2018 criteria:\n\n   1. LTB: 3 to 7 RBC units from at least 2 transfusion episodes in the 16-week period before administration of the first dose of study drug AND \\<4 RBC units in the 8-week period before administration of the first dose of study drug, or\n   2. HTB: ≥8 RBC units in the 16-week period before administration of the first dose of study drug AND ≥4 RBC units in the 8-week period before administration of the first dose of study drug\n\n   If a participant's transfusion burden does not fall into either the LTB or HTB category, as defined per IWG 2018 criteria, then the transfusion burden will be categorized based on their transfusion history in the 16-week period before administration of the first dose of study drug.\n4. Pretransfusion Hb concentration available for a minimum of 2 and at least half (50%) of the transfusions received in the 16-week period before administration of the first dose of study drug\n5. A Hb concentration \\<10.0 g/dL during the 4-week Screening Period;\n6. Up to 2 prior therapies including erythropoiesis-stimulating agents (ESAs) (eg, erythropoietin \\[EPO\\], EPO + granulocyte colony-stimulating factor \\[G-CSF\\]) and/or luspatercept;\n7. ECOG Performance Status score of 0, 1, or 2;\n8. If taking iron chelation therapy, the iron chelation therapy dose must have been stable and started ≥56 days before administration of the first dose of study drug;\n9. WOCBP must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use a highly effective, from the time of providing informed consent throughout the study and for 28 days after the last dose of study drug; if the highly effective method of contraception is hormonal contraception, then an acceptable barrier method must be used. Men with partners who are WOCBP must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use a condom from the time of providing informed consent throughout the study and for 28 days after the last dose of study drug;\n10. Written informed consent from the participant before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.\n\nExclusion Criteria:\n\nPhase 2a\n\n1. Known history of acute myeloid leukemia (AML);\n2. Secondary MDS, defined as MDS that is known to have arisen as a result of chemical injury or treatment with chemotherapy and/or radiation for other diseases;\n3. Prior exposure to a pyruvate kinase activator and/or disease-modifying agents for underlying MDS:\n\n   * Immunomodulatory drugs (IMiDs) such as lenalidomide; at the Investigator's discretion and in consultation with the Medical Monitor, participants who received ≤1 week of treatment with IMiDs may not be excluded, provided their last dose was ≥8 weeks before administration of the first dose of study drug\n   * Hypomethylating agents (HMAs); at the Investigator's discretion and in consultation with the Medical Monitor, participants who received ≤2 doses of HMAs may not be excluded, provided that their last dose was ≥8 weeks before administration of the first dose of study drug\n   * Isocitrate dehydrogenase (IDH) inhibitors\n   * Immunosuppressive therapy (IST)\n   * Allogeneic or autologous stem cell transplant;\n4. Currently receiving treatment with ESAs±G-CSF and/or luspatercept. Treatment with ESAs±G-CSF must have been stopped for ≥28 days before administration of the first dose of study drug; treatment with luspatercept must have been stopped for ≥65 days before administration of the first dose of study drug;\n5. History of active and/or uncontrolled cardiac or pulmonary disease within 6 months before providing informed consent, including but not limited to:\n\n   * New York Heart Association Class III or IV heart failure or clinically significant dysrhythmia\n   * Myocardial infarction, unstable angina pectoris, or unstable hypertension; high risk thrombosis; hemorrhagic, embolic, or thrombotic stroke; deep venous thrombosis; or pulmonary or arterial embolism\n   * Heart rate-corrected QT interval using Fridericia's method of ≥470 milliseconds for female participants and ≥450 milliseconds for male participants, except for right or left bundle branch block\n   * Severe pulmonary fibrosis as defined by severe hypoxia, evidence of right-sided heart failure, and radiographic pulmonary fibrosis \\>50%\n   * Severe pulmonary hypertension as defined by severe symptoms associated with hypoxia, right-sided heart failure, and oxygen indicated;\n6. History of hepatobiliary disorders, as defined by:\n\n   * Serum aspartate aminotransferase (AST) \\>2.5 × upper limit of normal (ULN) (unless due to hemolysis and/or hepatic iron deposition) and alanine aminotransferase (ALT) \\>2.5 × ULN (unless due to hepatic iron deposition)\n   * Serum bilirubin \\>ULN, if the elevation is associated with clinically symptomatic choledocholithiasis, cholecystitis, biliary obstruction, or hepatocellular disease;\n7. Renal dysfunction, as defined by an estimated glomerular filtration rate (eGFR) \\<45 milliliters per minute (mL/min)/1.73 m\\^2;\n8. Active infection requiring systemic antimicrobial therapy at the time of providing informed consent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before administration of the first dose of study drug;\n9. Major surgery within 12 weeks before administration of the first dose of study drug. Participants must have completely recovered from any previous surgery before administration of the first dose of study drug;\n10. For any malignancy except MDS: History of malignancy (active or treated) ≤5 years before providing informed consent for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;\n11. Positive test for hepatitis C virus (HCV) antibody (Ab) with evidence of active HCV infection, or positive test for hepatitis B surface antigen (HBsAg);\n12. Positive test for HIV-1 Ab or HIV-2 Ab;\n13. Absolute neutrophil count (ANC) \\<500/microliter (μL) (0.5 × 10\\^9/L);\n14. Platelet count ≤75,000/μL during Screening (75 × 10\\^9/L) platelet transfusions within 28 days before Screening or during Screening;\n15. Nonfasting triglyceride concentration \\>500 mg/dL;\n16. Receiving inhibitors of P-glycoprotein (P-gp) that have not been stopped for ≥5 days or a time frame equivalent to 5 half-lives (whichever is longer) before administration of the first dose of study drug;\n17. Current enrollment or past participation (within 4 weeks or a time frame equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug or, whichever is longer) in any other clinical study involving an investigational treatment or device;\n18. Known allergy to tebapivat or its excipients;\n19. Pregnant or breastfeeding;\n20. Any medical, hematologic, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:\n\n    * Participants who are institutionalized by regulatory or court order;\n    * Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).\n\nPhase 2b\n\n1. Known history of AML;\n2. Secondary MDS, defined as MDS that is known to have arisen as a result of chemical injury or treatment with chemotherapy and/or radiation for other diseases;\n3. Prior exposure to a pyruvate kinase activator, including exposure to tebapivat in the Phase 2a part of this study, and/or disease-modifying agents for underlying MDS:\n\n   * Imetelstat; at the Investigator's discretion and in consultation with the Medical Monitor, participants who received ≤2 doses of imetelstat may not be excluded, provided that their last dose was ≥8 weeks before administration of the first dose of study drug\n   * IMiDs such as lenalidomide; at the Investigator's discretion and in consultation with the Medical Monitor, participants who received ≤1 week of treatment with IMiDs may not be excluded, provided their last dose was ≥8 weeks before administration of the first dose of study drug\n   * HMAs; at the Investigator's discretion and in consultation with the Medical Monitor, participants who received ≤2 doses of HMAs may not be excluded, provided that their last dose was ≥8 weeks before administration of the first dose of study drug\n   * IDH inhibitors\n   * IST\n   * Allogeneic or autologous stem cell transplant;\n4. Currently receiving treatment with ESAs±G-CSF and/or luspatercept. Treatment with ESAs±G-CSF must have been stopped for ≥28 days before administration of the first dose of study drug; treatment with luspatercept must have been stopped for ≥65 days before administration of the first dose of study drug;\n5. History of active and/or uncontrolled cardiac or pulmonary disease within 6 months before providing informed consent, including but not limited to:\n\n   * New York Heart Association Class III or IV heart failure or clinically significant dysrhythmia\n   * Myocardial infarction, unstable angina pectoris, or unstable hypertension; high risk thrombosis; hemorrhagic, embolic, or thrombotic stroke; deep venous thrombosis; or pulmonary or arterial embolism\n   * Heart rate-corrected QT interval using Fridericia's method of ≥470 milliseconds for female participants and ≥450 milliseconds for male participants, except for right or left bundle branch block\n   * Severe pulmonary fibrosis as defined by severe hypoxia, evidence of right-sided heart failure, and radiographic pulmonary fibrosis \\>50%\n   * Severe pulmonary hypertension as defined by severe symptoms associated with hypoxia, right-sided heart failure, and oxygen indicated\n6. History of hepatobiliary disorders, as defined by:\n\n   * Serum AST \\>2.5 × ULN (unless due to hemolysis and/or hepatic iron deposition) and ALT \\>2.5 × ULN (unless due to hepatic iron deposition)\n   * Serum bilirubin \\>ULN, if the elevation is associated with clinically symptomatic choledocholithiasis, cholecystitis, biliary obstruction, or hepatocellular disease\n7. Renal dysfunction, as defined by an eGFR \\<45 mL/min/1.73 m\\^2;\n8. Active infection requiring systemic antimicrobial therapy at the time of providing informed consent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before administration of the first dose of study drug;\n9. Major surgery within 12 weeks before administration of the first dose of study drug. Participants must have completely recovered from any previous surgery before administration of the first dose of study drug;\n10. For any malignancy except MDS: History of malignancy (active or treated) ≤5 years before providing informed consent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.;\n11. Positive test for HCV Ab with evidence of active HCV infection, or positive test for HBsAg;\n12. Positive test for HIV-1 Ab or HIV-2 Ab;\n13. ANC \\<500/μL (0.5 × 10\\^9/L);\n14. Platelet count \\< 75,000/μL (75 × 10\\^9 /L) during Screening; platelet transfusions within 28 days before Screening or during Screening;\n15. Nonfasting triglyceride concentration \\>500 mg/dL;\n16. Receiving inhibitors of P-gp that have not been stopped for ≥5 days or a time frame equivalent to 5 half-lives (whichever is longer) beforeadministration of the first dose of study drug;\n17. Current enrollment or past participation (within 4 weeks or a time frame equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug or, whichever is longer) in any other clinical study involving an investigational treatment or device;\n18. Known allergy to tebapivat or its excipients;\n19. Pregnant or breastfeeding;\n20. Any medical, hematologic, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:\n\n    * Participants who are institutionalized by regulatory or court order\n    * Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).\n21. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, autoimmune or hereditary hemolytic anemia, hypothyroidism, or any type of known clinically significant bleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Medical Affairs","affiliation":"Agios Pharmaceuticals, Inc.","role":"STUDY_CHAIR"}],"locations":[{"facility":"Innovative Clinical Research Institute Whittier","city":"Lakewood","state":"California","zip":"90805","country":"United States","geoPoint":{"lat":33.85363,"lon":-118.13396}},{"facility":"David Geffen School of Medicine at UCLA","city":"Los Angeles","state":"California","zip":"90024","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Emad Ibrahim, MD, Inc.","city":"Redlands","state":"California","zip":"92373","country":"United States","geoPoint":{"lat":34.05557,"lon":-117.18254}},{"facility":"Smilow Cancer Hospital at Yale New Haven","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Mayo Clinic Jacksonville - PPDS","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Edward H. Kaplan MD & Associates","city":"Skokie","state":"Illinois","zip":"60076","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"Washington University School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"Long Island City","state":"New York","zip":"11101","country":"United States","geoPoint":{"lat":40.74482,"lon":-73.94875}},{"facility":"Duke Adult Blood and Marrow Clinic","city":"Durham","state":"North Carolina","zip":"27705","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Monash Health, Monash Medical Centre","city":"Clayton","state":"Victoria","zip":"3168","country":"Australia","geoPoint":{"lat":-37.91667,"lon":145.11667}},{"facility":"Ordensklinikum Linz GmbH Elisabethinen","city":"Linz","state":"Upper Austria","zip":"4020","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Fakultni nemocnice Ostrava","city":"Ostrava","zip":"708 52","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Hôpital de La Conception","city":"Marseille","state":"Bouches-du-Rhône","zip":"13010","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"CHU Angers","city":"Angers","state":"Maine-et-Loire","zip":"49933","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"CHRU Lille","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Hôpital Saint Louis","city":"Paris","zip":"75475","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Medizinische Hochschule Hannover","city":"Hanover","state":"Lower Saxony","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Universitatsklinikum Dusseldorf","city":"Düsseldorf","state":"North Rhine-Westphalia","zip":"40225","country":"Germany","geoPoint":{"lat":51.22172,"lon":6.77616}},{"facility":"Universitatsklinikum Leipzig","city":"Leipzig","state":"Saxony","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"University Hospital of Alexandroupolis","city":"Alexandroupoli","country":"Greece","geoPoint":{"lat":40.84995,"lon":25.87644}},{"facility":"Attikon University General Hospital","city":"Athens","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"University General Hospital of Patras","city":"Pátrai","country":"Greece","geoPoint":{"lat":38.2462,"lon":21.73508}},{"facility":"Hippokration Hospital","city":"Thessaloniki","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Shaare Zedek Medical Center","city":"Jerusalem","zip":"9103102","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Tel Aviv Sourasky Medical Center PPDS","city":"Tel Aviv","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico","city":"Milan","state":"Lombardy","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Fondazione IRCCS Policlinico San Matteo di Pavia","city":"Pavia","state":"Lombardy","country":"Italy","geoPoint":{"lat":45.19205,"lon":9.15917}},{"facility":"Istituto Clinico Humanitas","city":"Rozzano","state":"Lombardy","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Azienda Ospedaliera Ordine Mauriziano di Torino","city":"Turin","state":"Piedmont","country":"Italy","geoPoint":{"lat":45.07049,"lon":7.68682}},{"facility":"Fondazione PTV Policlinico Tor Vergata","city":"Roma","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"MTZ Clinical Research Powered by PRATIA - PPDS","city":"Warsaw","state":"Masovian Voivodeship","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Pratia Onkologia Katowice - PRATIA - PPDS","city":"Katowice","state":"Silesian Voivodeship","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"SPZOZ MiSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie","city":"Olsztyn","state":"Warmian-Masurian Voivodeship","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Kyungpook National University Hospital","city":"Daegu","zip":"41944","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Asan Medical Center - PPDS","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic University of Korea, Seoul St. Mary's Hospital","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"C.H. Regional Reina Sofia - PPDS","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Hospital Universitario La Paz - PPDS","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario HM Sanchinarro - CIOCC","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Complejo Asistencial Universitario de Salamanca - H. Clinico","city":"Salamanca","zip":"37007","country":"Spain","geoPoint":{"lat":40.96882,"lon":-5.66388}},{"facility":"Hospital Universitario Virgen del Rocio - PPDS","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Aberdeen Royal Infirmary - PPDS","city":"Aberdeen","state":"Aberdeen City","zip":"AB25 2ZN","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"Western General Hospital Edinburgh - PPDS","city":"Edinburgh","zip":"EH24 2XU","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Kings College Hospital","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Churchill Hospital-NHS Oxford","city":"Oxford","zip":"OX3 7LE","country":"United Kingdom","geoPoint":{"lat":51.75222,"lon":-1.25596}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D009190","term":"Myelodysplastic Syndromes"},{"id":"D000740","term":"Anemia"}],"ancestors":[{"id":"D001855","term":"Bone Marrow Diseases"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"}]}},"hasResults":false}
]}